Main > NEUROLOGY. > Alzheimer's Disease > Vaccines > Co.: USA. I. (Development/Patent) > Patent>Validation in 19 Countries > Press Release:
Co. Obtains Validation of European Patent for Alzheimer s Vaccine in 19 Countries
September 19, 2007
FOR IMMEDIATE RELEASE
Co. Obtains Validation of European Patent for Alzheimer s Vaccine in 19 Countries
New Patent Underscores Co. s Leadership in Immunotherapy for Alzheimer s Disease
New York, NY, September 19, 2007 / Co., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer s disease and related disorders, announced today that European Patent No. ... covering chimeric peptide vaccines has been validated in nineteen European countries. The nine month opposition period for the patent expired on August 8, 2007. The patent also has been granted in several other countries outside of Europe. Co. is the exclusive assignee of the patent, which relates to the Co. s TradeMark technology.
“The validation of our patent in Europe strengthens our competitive advantage in a therapeutic area that is a front runner in the attack against Alzheimer s disease,” commented Co. s Chairman and Chief Executive Officer. “We are excited about this promising technology that possesses a unique combination of safety features, which potentially enables it to be used to treat patients suffering from Alzheimer s disease and also to prevent or delay the onset of this devastating disease.”
“There are multiple challenges in developing a means to safely immunize elderly individuals and avoid the failures encountered in previous clinical trials sponsored by major pharmaceutical companies,” commented Prof...(Co. s Chairman & CEO s brother). Prof. ... is the inventor of TradeMark Technology and is a member of Co. s Scientific Advisory Board. Professor .... added: “The major challenges are the need to: mount a robust immune response when the immune system has become senescent as the result of age; avoid autoimmune reactions; and ensure that the antibodies generated do not interfere with the normal physiological functions of the Amyloid Precursor Protein. TRadeMark Technology is specifically designed to address these issues.”
Press Release:'s products
This section has no products